Mounjaro®
Starting from £179.99/mo
Start journey Learn moreAnaemia is not a listed side effect of Mounjaro (tirzepatide) in its UK prescribing information, and there is no established causal link between tirzepatide and anaemia in the published clinical trial data. That said, some people on Mounjaro do notice low energy or pallor, and the question of whether the two are connected is a reasonable one to bring to a prescriber. This page sets out what the evidence does and doesn't say, and what to do if you're concerned. These are prescription-only medicines assessed individually by a clinician; nothing here replaces that clinical conversation.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, followed over 2,500 adults with obesity over 72 weeks, with tirzepatide producing an average body-weight reduction of around 20–21% at the 15mg dose. Adverse events were systematically recorded throughout. Anaemia was not among the common adverse reactions identified, and it does not appear in Mounjaro's UK-authorised prescribing information on the eMC as a recognised side effect at any dose level.
That absence matters. Thousands of adults were monitored closely, with blood tests at multiple points, and haematological problems did not emerge as a signal. So if you've read somewhere that Mounjaro causes anaemia as a rule, that claim outruns the current evidence.
Where things get more nuanced is in the downstream effects of significantly reduced food intake. Tirzepatide works, in part, by reducing appetite quite substantially. For some people that's a dramatic change. If meals shrink sharply in size and variety, the dietary supply of iron, vitamin B12 and folate can fall. All three are essential to red blood cell production. A genuine nutritional shortfall, sustained over months, could contribute to anaemia, not because the medicine is toxic to the blood, but because eating far less means absorbing far less. This is a real consideration on any effective weight-loss treatment, not unique to Mounjaro, and our tirzepatide PubMed research roundup brings together the peer-reviewed studies that explore these broader metabolic effects in more depth. You can read more about tirzepatide's broader clinical profile and mechanism on our dedicated page.
Tiredness is one of the more commonly reported experiences in the early weeks of Mounjaro treatment. The NHS patient information for tirzepatide lists fatigue as a recognised side effect alongside nausea and gastrointestinal symptoms. The mechanism here is usually straightforward: eating significantly less means taking in fewer calories, and the body registers that. Add in the GI adjustment period, where nausea or loose stools can reduce fluid and food intake further, and tiredness makes sense without any blood disorder being involved.
Dehydration is another culprit that often goes overlooked. If nausea is suppressing thirst, or vomiting has occurred, blood volume drops and fatigue follows quickly. Prescribers typically ask about fluid intake before they reach for an anaemia explanation.
That said, if fatigue is severe, persistent beyond the first few weeks, or accompanied by shortness of breath, pale skin, a rapid heartbeat or dizziness, those are reasons to contact a GP rather than wait. A full blood count is a routine, inexpensive test that will distinguish nutritional anaemia from other causes, and our page on Mounjaro and hypoglycemia is worth reading alongside this if you are trying to work out whether low blood sugar could be contributing to how you feel. If you're curious whether Mounjaro can directly cause anaemia rather than contribute to nutritional risk, our page on whether Mounjaro can cause anaemia looks at that question specifically.
It's also worth noting that weight loss itself (particularly rapid loss) can temporarily affect several haematological markers as the body recomposes. This is not the same as pathological anaemia, but it can produce readings that look unusual on a blood panel.
The practical response to this risk is nutritional attention, not alarm. People on Mounjaro are eating less by design; the job is to make that smaller intake count. Protein adequacy is the most-discussed concern, but iron, B12 and folate deserve equal attention, especially for anyone who already eats little red meat, follows a plant-based diet, or has a history of heavy periods.
Iron-rich foods (red meat, legumes, dark leafy greens, fortified cereals) can be worked into smaller meal volumes. Vitamin C alongside plant-based iron sources improves absorption. B12 is found almost exclusively in animal products, so people on plant-based diets taking Mounjaro may want a supplement reviewed with their GP or pharmacist. Folate sits in leafy vegetables, beans and fortified foods.
There is also a question about whether Mounjaro's slowing of gastric emptying affects absorption of oral iron or B12 supplements. No definitive evidence confirms a clinically meaningful interaction, but it's a sensible thing to mention if a prescriber recommends supplementation. You can find general information about Mounjaro as a treatment, including its mechanism, on our main Mounjaro page. For those thinking about the cost side of private treatment, our Mounjaro price guide covers what a complete private prescription typically includes. Broader questions about managing weight alongside other health considerations are covered across our weight-loss treatment overview.
If you are on Mounjaro and experiencing any of the following, contact your GP or the NHS 111 service rather than waiting for your next review: breathlessness on minimal exertion, heart palpitations, skin or gum pallor, prolonged dizziness on standing, or fatigue that is getting worse rather than better over time. These are the signs that warrant a blood test promptly.
Our clinical team reviews each patient's full picture before prescribing and before any repeat is approved, including any conditions that could affect treatment suitability. If something has changed between your consultations, getting in touch with our aftercare team is the right step. Mounjaro is not licensed for use in pregnancy, breastfeeding or by anyone trying to conceive, and it is not prescribed to those under 18. Anyone with a history of certain gastrointestinal or blood disorders will have that assessed at consultation.
If you have questions about how GLP-1 medicines interact with other aspects of your health, our frequently asked questions cover a wide range of clinical topics, and our clinical team is available for aftercare queries seven days a week. When you're ready to talk to a prescriber about whether Mounjaro is right for you, a free consultation with our team is the place to start.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.